Related Experiment Video
Updated: Apr 19, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Predicting High-Dose-Rate Brachytherapy Boost Benefit Using Hypoxia and Angiogenesis Gene Expression in Localised
T Lodhi1, M Reardon2, C G Quiles2
1Division of Cancer Sciences, University of Manchester, UK; Department of Clinical Oncology, The Christie Hospital NHS Trust, Manchester, UK.
Background:
High-dose-rate brachytherapy boost (HDR-BTb) combined with external beam radiotherapy (EBRT) improves biochemical relapse-free survival (bRFS) in localised prostate cancer (PCa) yet ∼21% of patients relapse despite dose escalation. Hypoxia and angiogenesis biomarkers have been linked to treatment outcomes through immunohistochemistry (IHC) but genomic validation at the transcriptomic level remains lacking. This study hypothesised that hypoxia- and angiogenesis-related gene expression profiles could predict clinical benefit from HDR-BTb escalation, refining patient selection.
Methods:
Whole transcriptome analysis using Clariom S microarrays was conducted within a phase III single-centre randomised controlled trial comparing EBRT alone versus EBRT+HDR-BTb. Primary and secondary endpoints were bRFS, metastasis-free survival (MFS), and overall survival (OS). Expression of CD34, SLC2A1, HIF1A, and SPP1 was evaluated alongside established 28- and 32-gene hypoxia signatures. Composite interaction terms combining high/low gene expression assessed joint biomarker effects. Statistical analyses included log-rank tests and Cox proportional hazards models performed using R (R Core Team, 2024). Differentially expressed genes (DEGs) and pathway enrichment analyses were obtained in EBRT and HDR-BTb patients with or without relapse.
Results:
Eighty-one men (EBRT+HDR-BTb = 39; EBRT = 42) were analysed (median follow-up: 131 months). High HIF1A and CD34 expression were prognostic for worse MFS (P = .01) and bRFS (P = .04), respectively. SPP1 and the 32-gene signature were associated with worse OS (P = .02). Predictive analysis showed HDR-BTb benefit in patients with low HIF1A (P = .004), low SLC2A1 (p = 0.04), low 32-gene scores (p = 0.047), and high CD34 (p = 0.02). A significant SLC2A1-CD34 interaction predicted HDR-BTb benefit (P = .017). In relapsed HDR-BTb patients, nine DEGs were identified and enriched for muscle and immune-related pathways, distinct from the 62 DEGs seen in the EBRT cohort, with no overlap.
Conclusion:
Gene expression had limited prognostic value, and relapse DEGs differed by treatment. Low SLC2A1, high CD34, and their interaction predicted HDR-BTb benefit. These findings support biomarker-led stratification using hypoxia-related signatures in PCa.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Regulation of Angiogenesis and Blood Supply
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...